What matters to patients and clinicians when discussing the impact of cancer medicines on health-related quality of life? Consensus-based mixed methods approach in prostate cancer

Abstract

Objective To identify what matters to clinicians and patients when discussing cancer medicines’ impact on health-related quality of life (HRQoL). Methods A framework of HRQoL domain/domain elements was developed, informed by analysis of published patient reported outcome measures (PROMs), applicable to prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique and questionnaire), prostate cancer clinicians and patients attending prostate cancer clinics and support groups were asked which domains/domain elements would be important to them when discussing the impact prostate cancer medicines have on their HRQoL. Results Twenty-one clinicians and 71 patients participated from the West of Scotland. Clinicians and patients identified 53/62 domain elements across seven domains as important, of which 32 (60%) were common to both groups. Clinicians placed more importance than patients on Mood & Emotion; in contrast, patients placed importance on a broader range of Symptoms & Side Effects, being informed about their care, and having effective healthcare professional collaboration. Conclusion This study provides insight into the similarities and differences between what clinicians and patients think is important when discussing the impact of cancer medicines on HRQoL. Future research should involve exploring the potential for consistency of medicines PROMs across different cancer types to support patient-clinician communication and drive improvements in care.

Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005–2020: an observational study

“…Efforts to develop and implement standardised HRQoL instruments tailored to specific cancer types as well as exploring the potential for consistent HRQoL measuring across different cancer types would facilitate better comparability of HRQoL outcomes and enhance the reliability of findings. 35 Furthermore, we identified substantial heterogeneity in the methods employed to analyse and present HRQoL outcomes. The most common modality observed in this study was the mean change in scores from baseline.…”

Testosterone Replacement Therapy in the Aged Male: Monitoring Patients’ Quality of Life Utilizing Scoring Systems

“…That diagnosis of prostatic malignancy is frequent in the male population might be a significant reason for QoL changes. 62 It has been reported TRT may neither have an impact on decision-making nor undermine early diagnosis of prostate cancer as the effect on prostate specific antigen (PSA) readings is minimal. 63 No effect on overall and specific mortality, and eventually in QoL is expected in selected men having received successful surgical treatment for prostate cancer who receive TRT.…”

Fatigue in Prostate Cancer: A Roundtable Discussion and Thematic Literature Review

“…In a qualitative study of 21 clinicians and 71 patients regarding the impact of cancer medicines on health-related quality of life, there was discordance between clinicians’ beliefs of what mattered the most to patients versus patients’ own beliefs [32] . For example, while clinicians were mindful of the impact of mood and emotion on quality of life and rated patient needs as high in this regard, patients ranked symptoms and side effects of treatment, the ability to ask questions during consultations, and health information more highly [32] .…”